Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease?

European Journal of Pharmacology

Volumn 346, Issue 1, 1998, Pages 1-13

  Benzi, Gianni ^a   Moretti, Antonio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease

Indexed keywords

AMIRIDINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HEPTYLSTIGMINE TARTRATE; HUPERZINE A; METRIFONATE; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE; ZANEPEZIL;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; CLINICAL TRIAL; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS;

EID: 0032478778     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00093-4     Document Type: Review

References (147)

1. Aisen P.S., Davis K.L. The search for disease-modifying treatment for Alzheimer's disease. Neurology. 48(Suppl. 6):1997;S35-S41.
2. Alder J.T., Chessell I.P., Bowen D.M. A neurochemical approach for studying response to acetylcholine in Alzheimer's disease. Neurochem. Res. 20:1995;769-771.
3. Alhainen K., Helkala E.-L., Reinikainen K., Riekkinen Sr. P. The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease. J. Neural Transm. 5:1993;185-192. (P-D Sect.).
4. Anand, R., Hartman, R.D., Hayes, P.E., Gharabawi, M., 1996. An overview of the development of SDZ ENA 713, a brain selective cholinesterase inhibitor. In: Becker, R., Giacobini, E. (Eds.), Alzheimer's Disease: From Molecular Biology to Therapy. Birkhäuser, Boston, pp. 239-243.
5. Appleyard M.E. Secreted acetylcholinesterase: non-classical aspects of a classical enzyme. Trends Neurosci. 15:1992;485-490.
6. Arendt T., Brückner M.K., Lange M., Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development. A study of molecular forms. Neurochem. Int. 21:1992;381-396.
7. Auld D.S., Kar S., Quirion R. β-Amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends Neurosci. 21:1998;43-49.
8. Bartus R.T., Dean III R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-414.
9. Baxter, M.G., Gallagher, M., 1997. Cognitive effects of selective loss of basal forebrain cholinergic neurons: implications for cholinergic therapies of Alzheimer's disease. In: Brioni, J.D., Decker, M.W. (Eds.), Pharmacological Treatment of Alzheimer's Disease: Molecular and Neurobiological Foundations. Wiley-Liss, New York, pp. 87-103.
10. Becker, R.E., Moriearty, P., Surbeck, R., Unni, L., Varney, A., Vicari, S.K., 1994. Second and third generation cholinesterase inhibitors: clinical aspects. In: Giacobini, E., Becker, R.E. (Eds.), Alzheimer's Disease: Therapeutic Strategies. Birkhäuser, Boston, pp. 172-178.
11. Becker R.E., Colliver J.A., Markwell S.J., Moriearty P.L., Unni L.K., Vicari S. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer's disease. Alzheimer Dis. Assoc. Dis. 10:1996;124-131.
12. Beeri R., Andres C., Lev-Lehman E., Timberg R., Huberman T., Shani M., Soreq H. Transgenic expression of human acetylcholinesterase induces progressive cognitive deterioration in mice. Curr. Biol. 5:1995;1063-1071.
13. Bowen D.M., Smith C.B., White P., Flack R.H.A., Carrasco L.H., Gedye J.L., Davison A.N. Chemical pathology of the organic dementias: II. Quantitative estimation of cellular changes in post-mortem brains. Brain. 100:1977;427-453.
14. 2-Adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat. Psychopharmacology. 124:1996;347-354.
15. Canal N., Imbimbo B.P., Lucchelli P.E. A 25-week, double-blind, randomized, placebo-controlled, trial of eptastigmine in patients with diagnosis of probable Alzheimer's disease. Eur. J. Neurol. 3:1996;238. suppl. 5.
16. Cowburn R.F., Fowler C.J., O'Neill C. Neurotransmitter receptor/G-protein mediated signal transduction in Alzheimer's disease brain. Neurodegeneration. 5:1996;483-488.
17. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 219:1983;1184-1190.
18. Crews F.T., Kurian P., Freund G. Cholinergic and serotoninergic stimulation of phosphoinositide hydrolysis is decreased in Alzheimer's disease. Life Sci. 55:1994;1993-2002.
19. Cuadra G., Giacobini E. Coadministration of cholinesterase inhibitors and idazoxan: effects of neurotransmitters in rat cortex in vivo. J. Pharm. Exp. Ther. 273:1995;230-240.
20. Cummings B.J., Pike C.J., Shankle R., Cotman C.W. β-Amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol. Aging. 17:1996;921-933.
21. Cummings, J., Bieber, F., Mas, J., Orazem, J., Gulanski, B., 1997. Metrifonate in Alzheimer's disease: results of a dose-finding study. In: Iqbal, K., Winblad, B., Nishimura, T., Takeda, M., Wisniewski, H.M. (Eds.), Alzheimer's Disease: Biology, Diagnosis and Therapeutics. Wiley, New York, pp. 665-669.
22. Cutler, N.R., Sramek, J.J., 1997. Considerations for clinical trials in Alzheimer's disease. In: Brioni, J.D., Decker, M.W. (Eds.), Pharmacological Treatment of Alzheimer's Disease: Molecular and Neurobiological Foundations. Wiley-Liss, New York, pp. 367-387.
23. Davies P., Maloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. ii:1976;1403.
24. Davis K.L., Powchik P. Tacrine. Lancet. 345:1995;625-630.
25. Davis J.N., Chisholm J.C. The 'amyloid cascade hypothesis' of AD: decoy or real McCoy? Trends Neurosci. 20:1997;558.
26. Davis K.L., Thal L.J., Gamzu E.R.et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. New Engl. J. Med. 327:1992;1253-1259.
27. Decker M.W., McGaugh J.L. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse. 7:1991;151-168.
28. DeKosky S.T., Harbaugh R.E., Schmitt F.A., Bakay R.A.E.et al. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Ann. Neurol. 32:1992;625-632.
29. + current. Eur. J. Pharmacol. 141:1987;153-157.
30. Eagger S.A., Harvey R.J. Clinical heterogeneity: responders to cholinergic therapy. Alzheimer Dis. Assoc. Dis. 9 (Suppl. 2):1995;37-42.
31. Eagger S.A., Levy R., Sahakian B.J. Tacrine in Alzheimer's disease. Lancet. 337:1991;989-992.
32. Enz A., Amstutz R., Boddeke H., Gmelin G., Malanowsky J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog. Brain Res. 98:1993;431-438.
33. Farber S.A., Nitsch R.M., Schulz J.G., Wurtman R.J. Regulated secretion of β-amyloid precursor protein in rat brain. J. Neurosci. 15:1995;7442-7451.
34. Farlow M., Gracon S.I., Hershey L.A., Lewis K.W., Sadowsky C.H., Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. J. Am. Med. Assoc. 268:1992;2523-2529.
35. 4) acetylcholinesterase: structure, localization and physiological regulation. J. Neurochem. 66:1996;1335-1346.
36. Fibiger H.C. Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends Neurosci. 14:1991;220-223.
37. Flynn D.D., Mash D.C. Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine. J. Pharmacol. Exp. Ther. 250:1989;573-581.
38. Flynn D.D., Ferrari-DiLeo G., Levey A.I., Mash D.C. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies. Life Sci. 56:1995;869-876.
39. Food and Drug Administration, 1991. An interim report from the FDA. New Engl. J. Med., 324, pp. 349-352.
40. Forloni G., Tagliavini R., Bugiani O., Salmona M. Amyloid in Alzheimer's disease and prion-related encephalopathies: studies with synthetic peptides. Prog. Neurobiol. 49:1996;287-315.
41. Foster, N.L., 1994. PET imaging. In: Terry, R.D., Katzman, R., Bick, K.L. (Eds.), Alzheimer's Disease. Raven Press, New York, pp. 87-103.
42. Frautschy S.A., Yang F., Calderón L., Cole G.M. Rodent models of Alzheimer's disease: rat aβ infusion approaches to amyloid deposits. Neurobiol. Aging. 17:1996;311-321.
43. Freeman S.E., Dawson R.M. Tacrine: a pharmacological review. Prog. Neurobiol. 36:1991;257-277.
44. Friedhoff L., Rogers S.L. Donezepil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease. Results of a preliminary evaluation. Neurology. 48:1997;A100.
45. 4 binding in Alzheimer's disease brain. Brain Res. 681:1995;160-166.
46. Geula, C., Mesulam, M.-M., 1994. Cholinergic systems and related neuropathological predilection patterns in Alzheimer's disease. In: Terry, R.D., Katzman, R., Bick, K.L. (Eds.), Alzheimer's Disease. Raven Press, New York, pp. 263-291.
47. Geula C., Mesulam M.-M. Cholinesterases and the pathology of Alzheimer's disease. Alzheimer Dis. Assoc. Dis. 9:1995;23-28. suppl. 2.
48. Giacobini E. Cholinergic receptors in human brain: effects of aging and Alzheimer's disease. J. Neurosci. Res. 27:1990;548-560.
49. Giacobini, E., 1996. Cholinesterase inhibitors do more than inhibit cholinesterase. In: Becker, R., Giacobini, E. (Eds.), Alzheimer's Disease: From Molecular Biology to Therapy. Birkhäuser, Boston, pp. 187-204.
50. Giacobini, E., Cuadra, G., 1994. Second and third generation cholinesterase inhibitors: from preclinical studies to clinical efficacy. In: Giacobini, E., Becker, R. (Eds.), Alzheimer's Disease: Therapeutic Strategies. Birkhäuser, Boston, pp. 155-171.
51. Giacobini E., Mori F., Buznikov A., Becker R. Cholinesterase inhibitors alter APP secretion and APP mRNA in rat cerebral cortex. Soc. Neurosci. Abstr. 21:1995;988.
52. Giacobini E., Zhu X.-D., Williams E., Sherman K.A. The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology. 35:1996;205-211.
53. Giovannelli L., Casamenti F., Scali C., Bartolini L., Pepeu G. Differential effects of amyloid peptides β-(1-40) and β-(25-35) injections into the rat nucleus basalis. Neuroscience. 66:1995;781-792.
54. Gómez-Ramos P., Morán M.A. Ultrastructural localization of butyrylcholinesterase in senile plaques in the brains of aged and Alzheimer's disease patients. Mol. Chem. Neuropathol. 30:1997;161-173.
55. Govoni S., Bergamaschi S., Racchi M., Battaini F., Binetti G., Bianchetti A., Trabucchi M. Cytosol protein kinase C downregulation in fibroblasts from Alzheimer's disease patients. Neurology. 43:1993;2581-2586.
56. Greenamyre J.T., Maragos W.F. Neurotransmitter receptors in Alzheimer's disease. Cerebrovasc. Brain Metab. Rev. 5:1993;61-94.
57. Greenwood A.F., Powers R.E., Jope R.S. Phosphoinositide hydrolysis, Gαq, phospholipase C, and protein kinase C in post mortem human brain: effects of post mortem interval, subject age, and Alzheimer's disease. Neuroscience. 69:1995;125-138.
58. Growdon J.H. Tacrine in Alzheimer's disease (Reply). New Engl. J. Med. 328:1993;810.
59. Hagan, J.J., Morris, R.G.M., 1988. The cholinergic hypothesis of memory: a review of animal experiments. In: Iversen, L.L., Iversen, S.D., Snyder, S.H. (Eds.), Handbook of Psychopharmacology, Vol. 20. Plenum, New York, pp. 237-323.
60. Hallak M., Giacobini E. Physostigmine, tacrine and metrifonate: the effect of multiple doses on acetylcholine metabolism in rat brain. Neuropharmacology. 28:1989;199-206.
61. Hanin, I., 1996. Pharmacological induction of cholinergic hypofunction as a tool for evaluating cholinergic therapies. In: Becker, R., Giacobini, E. (Eds.), Alzheimer's Disease: From Molecular Biology to Therapy. Birkhäuser, Boston, pp. 165-170.
62. Harrison P.J., Barton A.J.L., Najlerahim A., McDonald B., Pearson R.C.A. Increased muscarinic receptor messenger RNA in Alzheimer's disease temporal cortex demonstrated by in situ hybridization histochemistry. Mol. Brain Res. 9:1991;15-21.
63. Haug L.S., Østvold A.C., Cowburn R.F., Garlind A., Winblad B., Bogdanovich N., Walaas S.I. Decreased inositol (1,4,5)-trisphosphate receptor levels in Alzheimer's disease cerebral cortex: selectivity of changes and possible correlation to pathological severity. Neurodegeneration. 5:1996;169-176.
64. Höhmann, C., Antuono, P., Coyle, J.T., 1988. Basal forebrain cholinergic neurons and Alzheimer's disease. In: Iversen, L.L., Iversen, S.D., Snyder, S.H. (Eds.), Handbook of Psychopharmacology, Vol. 20. Plenum, New York, pp. 69-106.
65. Holttum J.R., Gershon S. The cholinergic model of dementia, Alzheimer's type: progression from the unitary transmitter concept. Dementia. 3:1992;174-185.
66. Horsburgh, K., Saitoh, T., 1994. Altered signal transduction in Alzheimer's disease. In: Terry, R.D., Katzman, R., Bick, K.L. (Eds.), Alzheimer's Disease. Raven Press, New York, pp. 387-404.
67. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
68. Inestrosa N.C., Alvarez A., Pérez C.A., Moreno R.D., Vicente M., Linker C., Casanueva O.I., Soto C., Garrido J. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron. 16:1996;881-891.
69. Jin L.-W., Saitoh T. Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy. Drugs Aging. 6:1995;136-149.
70. Jope R.S. Cholinergic muscarinic receptor signalling by the phosphinositide signal transduction system in Alzheimer's disease. Alzheimer Dis. Rev. 1:1996;2-14.
71. Jope R.S., Song L., Powers R.E. Cholinergic activation of phosphoinositide signalling is impaired in Alzheimer's disease brain. Neurobiol. Aging. 18:1997;111-120.
72. Kihara T., Shimohama S., Sawada H., Kimura J., Kume T., Kochiyama H., Maeda T., Akaike A. Nicotinic receptor stimulation protects neurons against β-amyloid toxicity. Ann. Neurol. 42:1997;159-163.
73. Knapp M.J., Knopman D.S., Solomon P.R., Pendlebury W.W., Davis C.S., Gracon S.I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. J. Am. Med. Assoc. 271:1994;985-991.
74. Knopman D., Schneider L., Davis K., Talwalker S., Smith F., Hoover T., Gracon S. Long-term tacrine (Cognex) treatment: effect on nursing home placement and mortality. Neurology. 47:1996;166-177.
75. 1 muscarinic receptor-G protein coupling in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 54:1995;783-789.
76. Lahiri D.K., Lewis S., Farlow M.R. Tacrine alters the secretion of the β-amyloid precursor protein in cell lines. J. Neurosci. Res. 37:1994;777-787.
77. Liberini P., Valerio A., Memo M., Spano P. Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease? TIPS. 17:1996;155-160.
78. Lyketsos C.G., Corazzini K., Steele C.D., Kraus M.F. Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. J. Neuropsychiatry Clin. Neurosci. 8:1996;67-73.
79. Madden S., Woolf T.F., Pool W.F., Park B.K. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Biochem. Pharmacol. 46:1993;13-20.
80. Maltby N., Broe G.A., Creasey H., Jorm A.F., Christensen H., Brooks W.S. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial. Br. Med. J. 308:1994;879-883.
81. Masliah E., Cole G.M., Hansen L.A., Mallory M., Albright T., Terry R.D., Saitoh T. Protein kinase C alteration is an early biochemical marker in Alzheimer's disease. J. Neurosci. 11:1991;2759-2767.
82. Messamore E., Warpman U., Ogane N., Giacobini E. Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex. Neuropharmacology. 32:1993;745-750.
83. Mimori Y., Nakamura S., Yukawa M. Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor. Behav. Brain Res. 83:1997;25-30.
84. Moran P.M., Higgins L.S., Cordell B., Moser P.C. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human β-amyloid precursor protein. Proc. Natl. Acad. Sci. USA. 92:1995;5341-5345.
85. Mori F., Cuadra G., Giacobini E. Metrifonate effects on acetylcholine and biogenic amines in rat cortex. Neurochem. Res. 20:1995;1081-1088.
86. Mori F., Lai C.-C., Fusi F., Giacobini E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. NeuroReport. 6:1995;633-636.
87. Mountjoy C.Q. Correlations between neuropathological and neurochemical changes. Br. Med. Bull. 42:1986;81-85.
88. Muir J.L. Acetylcholine, aging, and Alzheimer's disease. Neurobiol. Aging. 56:1997;687-696.
89. Müller W.E., Stoll L., Schubert T., Gelbmann C.M. Central cholinergic functioning and aging. Acta Psychiatr. Scand. Suppl. 366(Suppl.):1991;34-39.
90. Nalbantoglu J., Tirado-Santiago G., Lahsaïni A., Poirier J., Goncalves O., Verge G., Momoli F., Welner S.A., Massicotte G., Julien J.-P., Shapiro M.L. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature. 387:1997;500-505.
91. Nightingale S.L. Donepezil approved for treatment of Alzheimer's disease (from the Food and Drug Administration). J. Am. Med. Assoc. 277:1997;10.
92. Nilsson-Håkansson L., Lai Z., Nordberg A. Tetrahydroaminoacridine induces opposite changes in muscarinic and nicotinic receptors in rat brain. Eur. J. Pharmacol. 186:1990;301-305.
93. Nitsch R.M. From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease. Neurodegeneration. 5:1996;477-482.
94. Nitsch R.M., Growdon J.H. Role of neurotransmission in the regulation of amyloid β-protein precursor processing. Biochem. Pharmacol. 47:1994;1275-1284.
95. Nordberg A. Neuroreceptor changes in Alzheimer's disease. Cerebrovasc. Brain Metab. Rev. 4:1992;303-328.
96. Nordberg A., Lundqvist H., Hartvig P., Andersson J., Johansson M., Hellström-Lindahl E., Långström B. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Dement. Geriatr. Cogn. Disord. 8:1997;78-84.
97. Nordgren I., Karlén B., Kimland M. Metrifonate and tacrine: a comparative study on their effect on acetylcholine dynamics in mouse brain. Pharmacol. Toxicol. 71:1992;236-240.
98. Ogane N., Giacobini E., Messamore E. Preferential inhibition of acetylcholinesterase molecular forms in rat brain. Neurochem. Res. 17:1992;489-495.
99. Ogane N., Giacobini E., Struble R. Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer's disease brain. Brain Res. 589:1992;307-312.
100. Ohara K., Kondo N., Xie D., Tanabe K., Yamamoto T., Kosaka K., Miyasato K., Ohara K. Normal sequences of muscarinic acetylcholine receptors (m1 and m2) in patients with Alzheimer's disease and vascular dementia. Neurosci. Lett. 178:1994;23-26.
101. Palmer A.M. Neurochemical studies of Alzheimer's disease. Neurodegeneration. 5:1996;381-391.
102. Palmer A.M., Gershon S. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J. 4:1990;2745-2752.
103. Pepeu G. Acetylcholine and brain aging. Pharm. Res. Commun. 20:1988;91-97.
104. Pepeu G. Memory disorders: novel treatments, clinical perspective. Life Sci. 55:1994;2189-2194.
105. Perry E.K. The cholinergic hypothesis. Ten years on. Br. Med. Bull. 42:1986;63-69.
106. Rainer M. Galanthamine in Alzheimer's disease. A new alternative to tacrine? CNS Drugs. 7:1997;89-97.
107. Rogers S.L., Friedhoff L.T. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 7:1996;293-303.
108. Rogers S.L., Perdomo C., Friedhoff L.T. Clinical benefits are maintained during long-term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020 (abstract). Eur. Neuropsychopharmacol. 5:1995;386-387.
109. Rogers S.L., Doody R., Mohs R., Friedhoff L.T. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30-week phase III trial (abstract). Neurology. 46:1996;A217.
110. Santucci A.C., Haroutunian V., Davis K.L. Pharmacological alleviation of combined cholinergic/noradrenergic lesion-induced memory deficits in rats. Clin. Neuropharmacol. 14:1991;S1-S8.
111. Sarter M., Bruno J.P. Cognitive function of cortical acetylcholine: toward a unifying hypothesis. Brain Res. Rev. 23:1997;28-46.
112. Sarter M., Hagan J., Dudchenko P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing. Psychopharmacology. 107:1992;144-159. (part I).
113. Sarter M., Hagan J., Dudchenko P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing. Psychopharmacology. 107:1992;461-473. (part II).
114. Sarter, M., Bruno, J.P., Himmelheber, A.M., 1997. Cortical acetylcholine and attention: neuropharmacological and cognitive principles directing treatment strategies for cognitive disorders. In: Brioni, J.D., Decker, M.W. (Eds), Pharmacological Treatment of Alzheimer's Disease. Wiley-Liss, New York, pp. 105-128.
115. Sberna G., Sáez-Valero J., Beyreuther K., Masters C.L., Small D.H. The amyloid β-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. J. Neurochem. 69:1997;1177-1184.
116. Scali C., Giovannini M.G., Bartolini L., Prosperi C., Hinz V., Schmidt B., Pepeu G. Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats. Eur. J. Pharmacol. 325:1997;173-180.
117. Schegg K.M., Harrington L.S., Neilsen S., Zweig R.M., Peacock J.H. Soluble and membrane-bound forms of brain acetylcholinesterase in Alzheimer's disease. Neurobiol. Aging. 13:1992;697-704.
118. Schneider L.S. Clinical pharmacology of aminoacridines in Alzheimer's disease. Neurology. 43:1993;S64-S79. suppl. 4.
119. Selkoe D.J. Normal and abnormal biology of the β-amyloid precursor protein. Annu. Rev. Neurosci. 17:1994;489-517.
120. Siek G.C., Katz L.S., Fishman E.B., Korosi T.S., Marquis J.K. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer's disease brain. Biol. Psychiatr. 27:1990;573-580.
121. Small D.H., Michaelson S., Sberna G. Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Neurochem. Int. 28:1996;453-483. Critique by Greenfield, S., 485-490.
122. Soares J.C., Gershon S. THA. Historical aspects, review of pharmacological properties and therapeutic effects. Dementia. 6:1995;225-234.
123. Special Issue of Neurobiol. Aging, 1996. 17, No. 2.
124. Sramek J.J., Anand R., Wardle T.S., Irwin P., Hartman R.D., Cutler N.R. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci. 58:1996;1201-1207.
125. Summers W.K., Majovski L.V., Marsh G.M., Tachiki K., Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia. Alzheimer type. New Engl. J. Med. 315:1986;1241-1245.
126. Svensson, A.-L., Nordberg, A., 1997. Interaction of tacrine, galanthamine, NXX-066 and E2020 with neuronal α4β2 nicotinic receptors expressed in fibroblast cells. In: Iqbal, K., Winblad, B., Nishimura, T., Takeda, M., Wisniewski, H.M. (Eds.), Alzheimer's Disease: Biology, Diagnosis and Therapeutics. Wiley, New York, pp. 751-756.
127. Tariot P.N. Alzheimer's disease: an overview. Alzheimer Dis. Assoc. Dis. 8:1994;S4-S11.
128. Troetel, W.M., Imbimbo, B.P., 1997. Overview of the development of eptastigmine, a long-acting cholinesterase inhibitor. In: Iqbal, K., Winblad, B., Nishimura, T., Takeda, M., Wisniewski, H.M. (Eds.), Alzheimer's Disease: Biology, Diagnosis and Therapeutics. Wiley, New York, pp. 671-676.
129. Valenti G. Neuropeptide changes in dementia: pathogenetic implications and diagnostic value. Gerontology. 42:1996;241-256.
130. Xiao W.-B., Nordberg A., Zhang X. Effect of in vivo microdialysis of 1,2,3,4-tetrahydro-9-aminoacridine (THA) on the extracellular concentration of acetylcholine in the striatum of anesthetized rats. J. Pharmacol. Exp. Ther. 265:1993;759-764.
131. Wagstaff A.J., McTavish D. Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging. 4:1994;510-540.
132. Wallace M.A. Effects of Alzheimer's disease-related β-amyloid protein fragments on enzymes metabolizing phosphoinositides in brain. Biochim. Biophys. Acta. 1227:1994;183-187.
133. Wang H.-Y., Friedman E. Receptor-mediated activation of G proteins is reduced in post-mortem brains from Alzheimer's disease patients. Neurosci. Lett. 173:1994;37-39.
134. Wang S.-Z., Zhu S.-Z., Mash D.C., El-Fakahany E.E. Comparison of the concentration of messenger RNA encoding four muscarinic receptor subtypes in control and Alzheimer brains. Mol. Brain Res. 16:1992;64-70.
135. Wang H.-Y., Pisano M.R., Friedman E. Attenuated protein kinase C activity and translocation in Alzheimer's disease brain. Neurobiol. Aging. 15:1994;293-298.
136. Warpman U., Alafuzoff I., Nordberg A. Coupling of muscarinic receptors to GTP proteins in post-mortem human brain. Alterations in Alzheimer's disease. Neurosci. Lett. 150:1993;39-43.
137. Watkins P.B., Zimmerman H.J., Knapp J.M., Gracon S.I., Lewis K.W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. J. Am. Med. Assoc. 271:1994;992-998.
138. Weinstein H.C., Teunisse S., van Gool W.A. Tetrahydroaminoacridine and lecithin in the treatment of Alzheimer's disease. J. Neurol. 238:1991;34-38.
139. Weinstock M. The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update. Neurodegeneration. 4:1995;349-356.
140. Whitehouse P.J., Kalaria R.N. Nicotinic receptors and neurodegenerative dementing diseases: basic research and clinical implications. Alzheimer Dis. Assoc. Dis. 9(Suppl. 2):1995;3-5.
141. Wilcock, G., Wilkinson, D., 1997. Galanthamine hydrobromide: interim results of a group comparative, placebo-controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer type. In: Iqbal, K., Winblad, B., Nishimura, T., Takeda, M., Wisniewski, H.M. (Eds.), Alzheimer's Disease: Biology, Diagnosis and Therapeutics. Wiley, New York, pp. 661-665.
142. Williams, M., Arneric, S.P., 1997. Alzheimer's disease: prospects for treatment in the next decade. In: Brioni, J.D., Decker, M.W. (Eds.), Pharmacological Treatment of Alzheimer's Disease: Molecular and Neurobiological Foundations. Wiley-Liss, New York, pp. 525-542.
143. Wolf B.A., Wertkin A.M., Jolly Y.C., Yasuda R.P., Wolfe B.B., Konrad R.J., Manning D., Ravi S., Williamson J.R., Lee V.M.-Y. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid β-protein production in human neuronal NT2N cells. J. Biol. Chem. 270:1995;4916-4922.
144. Wolfson, C., Moride, Y., Perrault, A., Vida, S., 1997. A study of the efficacy, effectiveness and economic impact of tacrine in Alzheimer's disease. CCOHTA Publications, Ottawa, Canada.
145. Wright C.I., Geula C., Mesulam M.-M. Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 90:1993;683-686.
146. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 16:1996;921-932.
147. Younkin S.G., Goodridge B., Katz J., Lockett G., Nafziger D., Usiak M.F., Younkin L.H. Molecular forms of acetylcholinesterases in Alzheimer's disease. Fed. Proc. 45:1986;2982-2988.